- Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
- Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
- Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
- Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.50 |
---|---|
High | 5.50 |
Low | 5.12 |
Bid | 5.02 |
Offer | 5.50 |
Previous close | 5.39 |
Average volume | 1.41m |
---|---|
Shares outstanding | 76.11m |
Free float | 75.20m |
P/E (TTM) | -- |
Market cap | 410.23m USD |
EPS (TTM) | -4.98 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼